Home/Pipeline/pTTL (personalized Tumor-Targeting Lymphocytes)

pTTL (personalized Tumor-Targeting Lymphocytes)

Colorectal Cancer

Phase 1Active

Key Facts

Indication

Colorectal Cancer

Phase

Phase 1

Status

Active

Company

Neogap Therapeutics

About Neogap Therapeutics

Neogap Therapeutics is a privately held, clinical-stage biotech company based in Stockholm, Sweden, pioneering personalized T cell therapies for solid tumors. The company's core innovation is a two-part platform combining the PIOR® software for neoantigen prediction with the EpiTCer® method for T cell training and expansion. With a recent SEK 87 million financing round, Neogap is advancing its lead pTTL therapy through clinical development, initially targeting colorectal cancer patients with limited treatment options. The company operates from the Karolinska Institute campus, leveraging a strong academic and industry team.

View full company profile

Therapeutic Areas

Oncology Colorectal Cancer

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active